BioCardia’s (BCDA) Buy Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of BioCardia (NASDAQ:BCDA) in a research note issued to investors on Monday,Benzinga reports.

BCDA has been the topic of a number of other reports. Zacks Research raised shares of BioCardia from a “strong sell” rating to a “hold” rating in a research report on Tuesday, August 11th. Wall Street Zen raised shares of BioCardia from a “sell” rating to a “hold” rating in a research report on Saturday, August 15th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of BioCardia in a research report on Friday, July 17th. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $25.00.

BioCardia Stock Up 5.3%

NASDAQ BCDA opened at $1.19 on Monday. BioCardia has a twelve month low of $0.75 and a twelve month high of $2.29. The firm has a market capitalization of $18.02 million, a PE ratio of -1.86 and a beta of 0.48. The stock’s 50 day moving average is $0.97 and its 200 day moving average is $1.06.

BioCardia (NASDAQ:BCDA) last issued its quarterly earnings results on Wednesday, August 12th. The company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.18) by $0.05. On average, research analysts anticipate that BioCardia will post -0.71 earnings per share for the current year.

Insiders Place Their Bets

In related news, Director Simon H. Stertzer acquired 70,200 shares of the stock in a transaction on Monday, June 22nd. The stock was acquired at an average price of $0.92 per share, for a total transaction of $64,584.00. Following the completion of the purchase, the director owned 127,338 shares of the company’s stock, valued at $117,150.96. This represents a 122.86% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Over the last three months, insiders purchased 140,700 shares of company stock worth $131,966. 17.40% of the stock is owned by company insiders.

Institutional Investors Weigh In On BioCardia

A number of institutional investors have recently modified their holdings of BCDA. DRW Securities LLC purchased a new position in shares of BioCardia in the 4th quarter worth about $72,000. Geode Capital Management LLC grew its position in BioCardia by 70.4% during the 4th quarter. Geode Capital Management LLC now owns 66,003 shares of the company’s stock valued at $83,000 after purchasing an additional 27,263 shares during the last quarter. Finally, Cetera Investment Advisers bought a new stake in BioCardia during the 2nd quarter valued at about $40,000. 20.57% of the stock is owned by hedge funds and other institutional investors.

BioCardia Company Profile

BioCardia, Inc is a clinical-stage biotechnology company dedicated to developing novel cell-based therapies for patients with cardiovascular disease. The company’s core focus lies in advancing regenerative medicine approaches that address both chronic heart failure and acute myocardial infarction. BioCardia leverages proprietary delivery technologies to optimize the targeted administration of therapeutic cells directly into the heart muscle.

The company’s flagship products include the Helix Transendocardial Delivery System and the CardiAMP Cell Therapy System.